Technology Commercialization Office

Showing 10 result(s) for "Drugs/Pharmaceuticals"

A mechanism by which the inhibiting effects of drugs and other molecules on protein-protein interactions can be measured.

A novel set of molecules that inhibit integrin-linked kinase in order to suppress tumor cell growth and metastasis.

A novel anti-cancer agent (OSU-2S) that is devoid of S1P1 receptor activity and is highly effective in suppressing hepatocellular carcinoma tumor growth in vivo.

Parthenolide analogues derived from plants could be effective in treating leukemia or supplementing other treatments.

An anti-tumor agent developed from indol-3-carbinol, a naturally occurring phytochemical in cruciferous vegetables.

A new class of small-molecule cyclin D1 ablative agents based on troglitazone (TG) that repress intracellular cyclin D1 levels.

Development of thiazolidinedione (TZD), OSU-CG12, as a novel energy restriction-mimetic agent for cancer therapy and chemo-prevention.

A set of novel DNA methylation inhibitors that reduce DNA methylation by small molecule agents.

Estrogen Receptor Beta Agonists for the treatment of breast, colon, and prostate cancers as well as inflammatory diseases.

A new strategy for using androgen receptor ablative agents has been developed for prostate cancer therapy.